Sativex - Novel cannabis derived treatment for MS pain now available in Canada by prescription

    TORONTO, June 20 /CNW/ - Sativex(R) (Cannabis sativa L. extract), the
only adjunctive treatment for symptomatic relief of neuropathic pain in adults
with multiple sclerosis (MS), is now available in Canada. The novel treatment
can now be obtained by prescription through Canadian pharmacies. In April
2005, Canada became the first country in the world to approve Sativex, an
effective and safe cannabis derived prescription medicine.
    Health Canada has approved Sativex with conditions, under the Notice of
Compliance with Conditions (NOC/c) policy. This authorization reflects the
promising nature of the clinical evidence which will be confirmed with further
studies. Products approved under Health Canada's NOC/c policy, have
demonstrated promising benefit, are of high quality and possess an acceptable
safety profile based on a benefit/risk assessment for the approved use.
    "Effective pain control and management are extremely important in a
disease like MS," said Dr. Allan Gordon, Neurologist and Director of the
Wasser Pain Management Centre, and of the Edward Bronfman Family Foundation MS
Research Clinic at Mount Sinai Hospital, Toronto, Ontario. "The availability
of Sativex addresses the great demand for an effective treatment option in the
field of neuropathic pain in MS. Many patients, including some in my own
practice, report using cannabis for relief of their pain. People with MS and
neuropathic pain should speak to their doctor to determine whether Sativex is
an appropriate option for them."

Continued next Wednesday